Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InvionIVIXF -83.23%16 Equity-to-Asset is 0.71 as of Dec. 2025, which is 21% below its 10-year median of 0.90. GuruFocus rates IVIXF with a GF Score™ of 16/100 and a GF Value™ of $0.19. The stock has 1 warning sign investors should review. Among 1,006 Drug Manufacturers companies, Invion ranks better than 65.61% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Invion's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $3.79 Mil. Invion's Total Assets for the quarter that ended in Dec. 2025 was $5.37 Mil.
The historical rank and industry rank for Invion's Equity-to-Asset or its related term are showing as below:
IVIXF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.5 Med: 0.9 Max: 0.98
Current: 0.71
During the past 13 years, the highest Equity to Asset Ratio of Invion was 0.98. The lowest was 0.50. And the median was 0.90.
IVIXF's Equity-to-Asset is ranked better than 65.61% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs IVIXF: 0.71
Invion (OTCPK:IVIXF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Invion Equity-to-Asset Related Terms
Invion Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Invion's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Invion's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invion Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Invion's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Invion's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Invion's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invion (IVIXF) has a Equity-to-Asset of 0.71 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Invion and its competitors. This is 21% below median its historical median of 0.90. Over the past decade, Invion's Equity-to-Asset has ranged from 0.50 to 0.98. According to the industry distribution chart, Invion ranks #346 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 34.4%.
Is Invion's Equity-to-Asset too high?
Invion's current Equity-to-Asset of 0.71 is 21% below median its 10-year median of 0.90. Over the past 10 years, this metric has ranged from a low of 0.50 to a high of 0.98. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Invion's value of 0.71 is 16.4% above this industry median. Based on the distribution chart, Invion ranks #346 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Invion has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Invion's Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Invion ranks #346 out of 1006 companies for Equity-to-Asset. This puts Invion in the upper half of its industry. The industry median Equity-to-Asset is 0.61. Invion's value of 0.71 is 16.4% above this benchmark. Historically, Invion's own Equity-to-Asset has ranged from 0.50 to 0.98 over the past decade. While the company's 10-year median is 0.90 vs. the industry median of 0.61, Invion has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invion's current Equity-to-Asset of 0.71 is 16.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Invion and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invion's current Equity-to-Asset is 0.71, which is 21% below median its own 10-year median of 0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invion stock overvalued right now?
Invion (IVIXF) has a current Equity-to-Asset of 0.71. The stock's GF Value™ is $0.19, compared to a current price of $0.04 — trading 80.6% below its estimated fair value. The current Equity-to-Asset is 0.71, which is 21% below median its 10-year median of 0.90 and 16.4% above the Drug Manufacturers industry median of 0.61. Invion's overall GF Score™ is 16/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Invion (IVIXF), the current Equity-to-Asset is 0.71 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Invion (IVIXF) Overvalued in 2026?
Based on GuruFocus' analysis, Invion stock appears to be undervalued.
The current stock price of $0.04 is trading 80.6% below its estimated GF Value™ of $0.19.
Key valuation signals for IVIXF:
Equity-to-Asset: 0.71 (21% below median its 10-year median of 0.90)
GF Value™: $0.19 vs. price of $0.04 (80.6% below fair value)
Industry Position: 16.4% above the Drug Manufacturers median (#346 of 1006)
No single metric tells the full story. See the IVIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Invion Ltd is an Australian clinical-stage pharmaceutical drug development company. It is engaged in the development of PhotoDynamic Therapy (PDT) for cancer treatments called Photosoft, for the treatment of a range of cancers, and infectious diseases. The company produces topical and intravenous products suitable for use in skin cancer and solid tumors, such as ovarian, prostate, and lung cancer. Invion has developed a portfolio of patent protected compounds. Its drug candidate is INV043, a novel photosensitiser which has the potential to work as a therapy and a diagnostic tool.
16GF Score
Get the complete analysis for IVIXF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVIXF has been successfully added to your 
